Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model

Egyptian Liver Journal

Table 10 Classifying BCLC B cases into low- and high-risk groups for TACE according to the AFP model

		BCLC B		Test value	P value	Sig.
		Low-risk	High-risk
		No. = 14	No. = 53
Response	Complete response	12 (85.7%)	34 (70.8%)	1.730*	0.630	NS
	Partial response	2 (14.3%)	10 (20.8%)
	Stationary disease	0 (0.0%)	2 (4.2%)
	Progressive disease	0 (0.0%)	2 (4.2%)
Recurrence	No recurrence	4 (33.3%)	5 (14.7%)	1.956*	0.162	NS
Recurrence	Recurrence	8 (66.7%)	29 (85.3%)	1.956*	0.162	NS
Recurrence-free survival	Median (IQR)	12.5 (3–21)	6 (3–13)	− 0.934≠	0.351	NS
Recurrence-free survival	Range	3–32	3–30	− 0.934≠	0.351	NS
OS (months)	Median (IQR)	21 (14–28)	13 (10–19)	− 2.936≠	0.003	HS
OS (months)	Range	11–32	3–30	− 2.936≠	0.003	HS